Recent developments of HDAC inhibitors: Emerging indications and novel molecules

• Published in: British journal of clinical pharmacology Vol. 87; no. 12; pp. 4577 - 4597
• Main Authors: Bondarev, Andrey D., Attwood, Misty M., Jonsson, Jörgen, Chubarev, Vladimir N., Tarasov, Vadim V., Schiöth, Helgi B.
• Format: Journal Article
• Language: English
• Published: England 01.12.2021
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; belinostat; epigenetics; HDAC inhibition; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylase Inhibitors - therapeutic use; HIV Infections - drug therapy; Humans; panobinostat; romidepsin; vorinostat; HDAC inhibition; belinostat; vorinostat; romidepsin; panobinostat; epigenetics

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further...